Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Time to Buy?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw strong trading volume on Thursday. 8,929 shares traded hands during mid-day trading, an increase of 30% from the average daily volume of 6,863 shares. The stock last traded at $14.80 and had previously closed at $14.98.

Analysts Set New Price Targets

AAPG has been the subject of a number of analyst reports. BTIG Research reiterated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Citizens Jmp started coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 target price on the stock. Citigroup began coverage on Ascentage Pharma Group International in a research report on Wednesday, October 14th. They set a “buy” rating and a $46.00 price objective for the company. William Blair began coverage on Ascentage Pharma Group International in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. cut their target price on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research report on Thursday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company. Based on data from MarketBeat.com, Ascentage Pharma Group International has a consensus rating of “Buy” and a consensus target price of $43.90.

Ascentage Pharma Group International Stock Performance

The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09. The company has a 50-day moving average price of $15.98 and a two-hundred day moving average price of $20.34.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $22.24 million during the quarter. On average, equities analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.